

Đ;Đ^{3/4}Ñ,,ÑĈÑ•ĐÑĐ_μĐ»Đ,Đ^{1/2}Đ⁰

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1164005/publications.pdf>

Version: 2024-02-01

32
papers

554
citations

623734

14
h-index

642732

23
g-index

33
all docs

33
docs citations

33
times ranked

875
citing authors

#	ARTICLE	IF	CITATIONS
1	Cryo-electron microscopy of extracellular vesicles from cerebrospinal fluid. PLoS ONE, 2020, 15, e0227949.	2.5	106
2	Oligomeric Î±-synuclein and glucocerebrosidase activity levels in GBA-associated Parkinsonâ€™s disease. Neuroscience Letters, 2017, 636, 70-76.	2.1	61
3	Mutation analysis of Parkinson's disease genes in a Russian data set. Neurobiology of Aging, 2018, 71, 267.e7-267.e10.	3.1	40
4	Glucocerebrosidase gene mutations are associated with Parkinson's disease in Russia. Movement Disorders, 2012, 27, 158-159.	3.9	38
5	Increased plasma oligomeric alpha-synuclein in patients with lysosomal storage diseases. Neuroscience Letters, 2014, 583, 188-193.	2.1	35
6	Blood lysosphingolipids accumulation in patients with parkinson's disease with glucocerebrosidase 1 mutations. Movement Disorders, 2018, 33, 1325-1330.	3.9	34
7	Plasma Oligomeric Alpha-Synuclein Associated With Glucocerebrosidase Activity in Gaucher Disease. Movement Disorders, 2015, 30, 989-991.	3.9	28
8	Screening for LRRK2 mutations in patients with Parkinsonâ€™s disease in Russia: identification of a novel LRRK2 variant. European Journal of Neurology, 2008, 15, 692-696.	3.3	26
9	Ambroxol increases glucocerebrosidase (GCase) activity and restores GCase translocation in primary patient-derived macrophages in Gaucher disease and Parkinsonism. Parkinsonism and Related Disorders, 2021, 84, 112-121.	2.2	25
10	Plasma Cytokines Profile in Patients with Parkinsonâ€™s Disease Associated with Mutations in GBA Gene. Bulletin of Experimental Biology and Medicine, 2020, 168, 423-426.	0.8	24
11	SNCA, LRRK2, MAPT polymorphisms and Parkinson's disease in Russia. Parkinsonism and Related Disorders, 2013, 19, 1064-1065.	2.2	20
12	SNCA variants and alpha-synuclein level in CD45+ blood cells in Parkinsonâ€™s disease. Journal of the Neurological Sciences, 2018, 395, 135-140.	0.6	18
13	Whole-Exome Sequencing in Searching for New Variants Associated With the Development of Parkinsonâ€™s Disease. Frontiers in Aging Neuroscience, 2018, 10, 136.	3.4	17
14	Plasma cytokine profile in synucleinopathies with dementia. Journal of Clinical Neuroscience, 2020, 78, 323-326.	1.5	16
15	The frequency of cytochrome P450 2C9 genetic variants in the Russian population and their associations with individual sensitivity to warfarin therapy. Thrombosis Research, 2005, 115, 199-203.	1.7	13
16	Reduced Content of Î±-Synuclein in Peripheral Blood Leukocytes of Patients with LRRK2-Associated Parkinsonâ€™s Disease. Bulletin of Experimental Biology and Medicine, 2011, 150, 679-681.	0.8	9
17	Dataset of total, oligomeric alpha-synuclein and hemoglobin levels in plasma in Parkinson's disease. Data in Brief, 2017, 10, 182-185.	1.0	7
18	Human Peripheral Blood Macrophages As a Model for Studying Glucocerebrosidase Dysfunction. Cell and Tissue Biology, 2019, 13, 100-106.	0.4	6

#	ARTICLE	IF	CITATIONS
19	PREDICTORS OF ADVERSE CLINICAL COURSE OF CORONARY HEART DISEASE: THE RESULTS FROM DYNAMICAL OBSERVATION. Russian Journal of Cardiology, 2018, , 60-66.	1.4	6
20	Genetics variants and expression of the SCARB2 gene in the pathogenesis of Parkinson's disease in Russia. Neuroscience Letters, 2021, 741, 135509.	2.1	5
21	Increased Î±-Synuclein Level in <scp>CD45</scp>+ Blood Cells in Asymptomatic Carriers of <scp><i>GBA</i></scp> Mutations. Movement Disorders, 2021, 36, 1997-1998.	3.9	5
22	Regulation of ABCA1 and ABCG1 transporter gene expression in the intraabdominal adipose tissue. Biochemistry (Moscow) Supplement Series B: Biomedical Chemistry, 2016, 10, 327-334.	0.4	2
23	Apoptosis of peripheral blood lymphocytes in patients with LRRK2-associated Parkinsonâ€™s disease. Cell and Tissue Biology, 2012, 6, 171-175.	0.4	1
24	SNCA alleles rs356219 and rs356165 are associated with Parkinsonâ€™s disease and increased Î±-synuclein gene expression in CD45+ blood cells. Cell and Tissue Biology, 2016, 10, 277-283.	0.4	1
25	The Effect of Dopamine on Gene Expression of Alpha-synuclein and Transcription Factors GATA-1, GATA-2, and ZSCAN21 in Parkinsonâ€™s Disease. Cell and Tissue Biology, 2018, 12, 410-418.	0.4	1
26	P.114 Contribution of the SNCA gene and genes involved in autophagy in the pathogenesis of GBA-associated parkinson's disease. European Neuropsychopharmacology, 2021, 44, S10-S11.	0.7	1
27	Expression of Genes Encoding Nuclear Factors PPARÎ³, LXRÎ², and RORÎ± in Epicardial and Subcutaneous Adipose Tissues in Patients with Coronary Heart Disease. Bulletin of Experimental Biology and Medicine, 2021, 170, 654-657.	0.8	1
28	Genetic variants of SNCA, risk of Parkinsonâ€™s disease and alpha-synuclein level in CD45+ blood cells. European Neuropsychopharmacology, 2017, 27, S1032-S1033.	0.7	0
29	Investigation of Paraoxonase 1 Activity in Factory Workers Having Long-Term Contact with Organophosphorus Compounds. Russian Journal of Genetics: Applied Research, 2018, 8, 96-100.	0.4	0
30	P.359 Expression profile of genes involved in endolysosomal pathway in CD45+ blood cells as potential marker for differentiation of synucleinopathies. European Neuropsychopharmacology, 2020, 40, S208-S209.	0.7	0
31	P.101 Involvement of the genes related to lysosomal storage disorders in GBA-associated Parkinson's disease. European Neuropsychopharmacology, 2021, 44, S1-S2.	0.7	0
32	Investigation of paraoxonase 1 activity of the workers at the plant, who have long-term contact with organophosphorus compounds. Ecological Genetics, 2017, 15, 57.	0.5	0